OA10993A - Compostions pharmaceutiques pour le traitement de maladies virales - Google Patents

Compostions pharmaceutiques pour le traitement de maladies virales Download PDF

Info

Publication number: OA10993A
Authority: OA; OAPI
Prior art keywords: pharmaceutical composition; vsr; use according; pharmaceutically acceptable; active ingredient
Prior art date: 1996-09-11

Application number

OA9900054A

Other languages

English (en)

French (fr)

Inventor

Brigitte Konig

Jean-Pierre Rihoux

Wolfgang Konig

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-11

Filing date

1999-03-10

Publication date

2003-03-04

1999-03-10 Application filed by Ucb Sa filed Critical Ucb Sa

2003-03-04 Publication of OA10993A publication Critical patent/OA10993A/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
201000010099 disease Diseases 0.000 title claims abstract description 11
230000003612 virological effect Effects 0.000 title description 5
150000003839 salts Chemical class 0.000 claims abstract description 13
230000003287 optical effect Effects 0.000 claims abstract description 12
239000004480 active ingredient Substances 0.000 claims abstract description 6
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 27
230000000241 respiratory effect Effects 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 7
241000282412 Homo Species 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
-1 2- (2- (4- (4-chlorophenyl) phenylmethyl) -1-piperazinyl) ethoxy Chemical group 0.000 claims description 4
206010006448 Bronchiolitis Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
230000029812 viral genome replication Effects 0.000 claims description 3
208000021240 acute bronchiolitis Diseases 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
230000010076 replication Effects 0.000 claims description 2
239000000829 suppository Substances 0.000 claims description 2
239000006188 syrup Substances 0.000 claims description 2
235000020357 syrup Nutrition 0.000 claims description 2
208000009421 viral pneumonia Diseases 0.000 claims description 2
206010035737 Pneumonia viral Diseases 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
YZGQDNOIGFBYKF-UHFFFAOYSA-N Ethoxyacetic acid Chemical compound CCOCC(O)=O YZGQDNOIGFBYKF-UHFFFAOYSA-N 0.000 abstract 2
241000725643 Respiratory syncytial virus Species 0.000 abstract 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
102000004890 Interleukin-8 Human genes 0.000 description 21
108090001007 Interleukin-8 Proteins 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 20
229940096397 interleukin-8 Drugs 0.000 description 20
229960001803 cetirizine Drugs 0.000 description 19
210000003622 mature neutrocyte Anatomy 0.000 description 17
241000700605 Viruses Species 0.000 description 15
229920002477 rna polymer Polymers 0.000 description 11
238000002474 experimental method Methods 0.000 description 10
150000001875 compounds Chemical class 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000006698 induction Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000003714 granulocyte Anatomy 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000001387 anti-histamine Effects 0.000 description 4
239000000739 antihistaminic agent Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000750 progressive effect Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102000019034 Chemokines Human genes 0.000 description 3
108010012236 Chemokines Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
239000000463 material Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
208000037656 Respiratory Sounds Diseases 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000012429 reaction media Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
206010062106 Respiratory tract infection viral Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000002210 biocatalytic effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
GLNADSQYFUSGOU-UHFFFAOYSA-J chembl1640 Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-UHFFFAOYSA-J 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000021995 interleukin-8 production Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960004712 metrizoic acid Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000002433 mononuclear leukocyte Anatomy 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000003161 ribonuclease inhibitor Substances 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000012748 slip agent Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA9900054A 1996-09-11 1999-03-10 Compostions pharmaceutiques pour le traitement de maladies virales OA10993A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96870114		1996-09-11

Publications (1)

Publication Number	Publication Date
OA10993A true OA10993A (fr)	2003-03-04

Family

ID=8226163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900054A OA10993A (fr)	1996-09-11	1999-03-10	Compostions pharmaceutiques pour le traitement de maladies virales

Country Status (23)

Country	Link
US (1)	US6413970B1 (cs)
EP (1)	EP0936909A1 (cs)
JP (1)	JP2001500143A (cs)
KR (1)	KR20000036025A (cs)
CN (1)	CN1230116A (cs)
AP (1)	AP9901474A0 (cs)
AR (1)	AR009756A1 (cs)
AU (1)	AU717354B2 (cs)
BR (1)	BR9712033A (cs)
CA (1)	CA2265542A1 (cs)
CZ (1)	CZ83099A3 (cs)
EA (1)	EA001262B1 (cs)
HU (1)	HUP9904173A3 (cs)
ID (1)	ID21369A (cs)
IL (1)	IL128351A0 (cs)
NO (1)	NO991164L (cs)
NZ (1)	NZ334571A (cs)
OA (1)	OA10993A (cs)
PE (1)	PE107598A1 (cs)
PL (1)	PL332316A1 (cs)
TR (1)	TR199900523T2 (cs)
WO (1)	WO1998010764A1 (cs)
ZA (1)	ZA977874B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2324242A (en) *	1997-04-18	1998-10-21	Atindra Nath Chakrabarty	Medicaments for treating viral infections
IL147327A0 (en)	1999-06-28	2002-08-14	Janssen Pharmaceutica Nv	Respiratory syncytial virus replication inhibitors
ES2215670T3 (es) *	1999-06-28	2004-10-16	Janssen Pharmaceutica N.V.	Inhibidores de la replicacion del virus sincitial respiratorio.
SI1196408T1 (en) *	1999-06-28	2005-02-28	Janssen Pharmaceutica N.V.	Respiratory syncytial virus replication inhibitors
EP1521581B1 (en)	2002-07-02	2008-02-20	UCB Farchim S.A.	Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis
WO2004050647A2 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof
KR100698400B1 (ko)	2004-04-14	2007-03-23	이은주	탈모증 및 전립선비대증 치료를 위한 약제학적 조성물
CN102988346A (zh) *	2012-11-19	2013-03-27	何晓涛	Aphanamixoid A在抗呼吸道合胞病毒的药物中的应用
CN103356650A (zh) *	2013-07-04	2013-10-23	丁圣雨	Chukrasone A在抗呼吸道合胞病毒的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI75816C (fi) *	1981-02-06	1988-08-08	Ucb Sa	Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.

1997
- 1997-08-26 PE PE1997000761A patent/PE107598A1/es not_active Application Discontinuation
- 1997-09-02 ZA ZA977874A patent/ZA977874B/xx unknown
- 1997-09-08 CA CA002265542A patent/CA2265542A1/en not_active Abandoned
- 1997-09-08 BR BR9712033-2A patent/BR9712033A/pt not_active Application Discontinuation
- 1997-09-08 JP JP10513226A patent/JP2001500143A/ja active Pending
- 1997-09-08 WO PCT/EP1997/004859 patent/WO1998010764A1/en not_active Ceased
- 1997-09-08 PL PL97332316A patent/PL332316A1/xx unknown
- 1997-09-08 ID IDW990073A patent/ID21369A/id unknown
- 1997-09-08 TR TR1999/00523T patent/TR199900523T2/xx unknown
- 1997-09-08 CN CN97197831A patent/CN1230116A/zh active Pending
- 1997-09-08 EP EP97944846A patent/EP0936909A1/en not_active Withdrawn
- 1997-09-08 AP APAP/P/1999/001474A patent/AP9901474A0/en unknown
- 1997-09-08 EA EA199900226A patent/EA001262B1/ru not_active IP Right Cessation
- 1997-09-08 NZ NZ334571A patent/NZ334571A/xx unknown
- 1997-09-08 AU AU46213/97A patent/AU717354B2/en not_active Ceased
- 1997-09-08 US US09/254,548 patent/US6413970B1/en not_active Expired - Fee Related
- 1997-09-08 IL IL12835197A patent/IL128351A0/xx unknown
- 1997-09-08 CZ CZ99830A patent/CZ83099A3/cs unknown
- 1997-09-08 KR KR1019997002003A patent/KR20000036025A/ko not_active Withdrawn
- 1997-09-08 HU HU9904173A patent/HUP9904173A3/hu unknown
- 1997-09-11 AR ARP970104166A patent/AR009756A1/es not_active Application Discontinuation
1999
- 1999-03-10 NO NO991164A patent/NO991164L/no not_active Application Discontinuation
- 1999-03-10 OA OA9900054A patent/OA10993A/fr unknown

Also Published As

Publication number	Publication date
AP9901474A0 (en)	1999-03-31
NO991164D0 (no)	1999-03-10
HUP9904173A2 (hu)	2000-05-28
CN1230116A (zh)	1999-09-29
AU717354B2 (en)	2000-03-23
WO1998010764A1 (en)	1998-03-19
PE107598A1 (es)	1999-01-29
US6413970B1 (en)	2002-07-02
NO991164L (no)	1999-03-10
TR199900523T2 (xx)	1999-05-21
AR009756A1 (es)	2000-05-03
PL332316A1 (en)	1999-08-30
CA2265542A1 (en)	1998-03-19
ZA977874B (en)	1999-03-02
BR9712033A (pt)	2000-01-18
KR20000036025A (ko)	2000-06-26
IL128351A0 (en)	2000-01-31
ID21369A (id)	1999-05-27
HUP9904173A3 (en)	2001-04-28
JP2001500143A (ja)	2001-01-09
AU4621397A (en)	1998-04-02
EA001262B1 (ru)	2000-12-25
CZ83099A3 (cs)	1999-06-16
EA199900226A1 (ru)	1999-08-26
NZ334571A (en)	2000-10-27
EP0936909A1 (en)	1999-08-25

Publication	Publication Date	Title
Saneeymehri et al.	2015	Overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease
EP2969010B1 (en)	2017-10-11	Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US20190038603A1 (en)	2019-02-07	Methods of treating diseases characterised by vasoconstriction
EP3145513B1 (en)	2023-11-15	3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP6883917B2 (ja)	2021-06-09	結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤
JP2022511380A (ja)	2022-01-31	血清尿酸を低減させるための組成物
OA10993A (fr)	2003-03-04	Compostions pharmaceutiques pour le traitement de maladies virales
JP2011515469A (ja)	2011-05-19	シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
CN105163806A (zh)	2015-12-16	左西替利嗪和孟鲁司特在治疗过敏反应中的用途
CN103221043B (zh)	2016-04-06	用于治疗神经元连接发育障碍的erk抑制剂
CN102858329B (zh)	2015-06-17	用于治疗疾病的化合物
CN119868356B (zh)	2025-06-24	Cbl抑制剂nx1607在制备治疗动脉粥样硬化药物中的应用
MX2014012376A (es)	2015-06-05	Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio.
JP2022523018A5 (cs)	2023-02-01
JP7594124B2 (ja)	2024-12-03	Ｌｏｕ０６４を使用した治療の方法
CN111936137A (zh)	2020-11-13	用于治疗严重便秘的组合物和方法
CN104887655A (zh)	2015-09-09	乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
US20250221947A1 (en)	2025-07-10	Methods for treating a coronavirus infection using valproic acid and docosahexaenoic acid
EP1389120B1 (fr)	2012-08-01	Utilisation de la nystatine pour le traitement de l'athérosclérose liée à la présence de champignons parasites
RU2830584C1 (ru)	2024-11-22	Ингибиторы cxcl8 для применения в лечении covid-19
CN104888189B (zh)	2017-09-29	3‑氨基‑2‑羟基‑4‑苯基‑缬氨酰‑异亮氨酸类似物的新应用
MXPA99002240A (en)	2000-02-02	Pharmaceutical composition for treating viral diseases
CN104984318B (zh)	2018-02-06	3‑氨基‑2‑羟基‑4‑苯基‑缬氨酰‑异亮氨酸的新应用
CN118593506A (zh)	2024-09-06	一种化合物a或其衍生物在制备预防和治疗肝纤维化疾病的药物中的应用
CN112843065A (zh)	2021-05-28	一种用于认知障碍的药物及其制备方法